SEC Tracker
Get the app
PRTA · XBRL financial data

Prothena Corporation Public Limited Company financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PRTA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers850*013212*3420*511
Research and development5862*64585150*51412915*139
General and administrative1717*17161717*18161313*1311
Total operating expenses7579*82746767*68894324*2122
Operating income (loss)10(79)*(82)58(67)(65)*(66)(85)(40)(24)*30(21)
Other income (expense)(0)(0)*(0)(0)(0)0*(0)(0)(0)(0)*0(0)
Income tax expense (benefit)(3)(3)*(2)(2)(1)(2)*(1)45(0)0*00
Net income (loss)22(67)*(72)67(59)(58)*(60)(126)(37)(22)*33(19)
Earnings per share, basic USD per share0.41(1.26)*(1.34)1.24(1.10)(1.08)*(1.12)(2.34)(0.68)(0.40)*0.61(0.36)
Earnings per share, diluted USD per share0.38—(1.34)1.22(1.10)(1.10)*(1.12)(2.34)(0.68)(0.40)*0.60(0.36)
Weighted average shares, basic millions of shares5454*54545454*54545454*5452
Weighted average shares, diluted millions of shares5849*54555453*54545454*5452

Balance sheet

CSV

Fiscal quarters (PRTA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents671619547564519471418371331308329288
Accounts receivable550000——————
Prepaid and other current assets131418221614181498104
Total current assets691639566586535485436385340315339292
Property and equipment, net244333332222
Right-of-use asset13121312111110109877
Total assets747696623646595547495399353327350303
Accounts payable1925149108161211642
Total current liabilities535743474649486851413312
Lease liability, non-current911101098876554
Total liabilities130135121646160587558463716
Accumulated deficit(913)(980)(1,052)(985)(1,044)(1,102)(1,163)(1,288)(1,325)(1,346)(1,314)(1,332)
Total stockholders' equity617561502582534487438324295280313287
Total liabilities and equity747696623646595547495399353327350303
Common shares outstanding (cover page) millions of shares545454545454545454545251

Cash flows

CSV

Fiscal quarters (PRTA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)22(67)*(72)67(59)(58)*(60)(126)(37)(22)*33(19)
Stock-based compensation1111*12121111*111277*78
Depreciation and amortization0*0*00*0*0*00*0*0*00*
Net cash from operating activities10*(51)*(73)16*(45)*(48)*(53)(46)*(41)*(23)*29(25)*
Net cash from investing activities(0)*(2)*(0)(0)*(0)*(0)*(0)(0)*(0)*0*0(1)*
Net cash from financing activities3*0*10*0*(0)*(0)(0)*(0)*0*(7)(16)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Prothena Corp Public2881(25)*51.3M11.5 quarters 10-QJun 30, 2026
Altimmune63not reported(24)*194.5M13.5 quarters 10-QJun 30, 2026
Usana Health Sciences16922323*18.5M— 10-QJul 4, 2026
Rigel Pharmaceuticals617931*18.7M— 10-QJun 30, 2026
Aura Biosciences68not reported(33)*103.7M2.1 quarters 10-QJun 30, 2026
Amarin157409.2*not reported— 10-QSep 30, 2026
Nektar Therapeutics3910(76)*34.1M9.0 quarters 10-QJun 30, 2026
Northwest Biotherapeutics0.60.8(7.2)*1.7B0.1 quarters 10-QJun 30, 2026
Emergent BioSolutions176110100*51.4M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.